{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T05:00:58Z","timestamp":1777784458141,"version":"3.51.4"},"reference-count":56,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2017,8,7]],"date-time":"2017-08-07T00:00:00Z","timestamp":1502064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Int J Artif Organs"],"published-print":{"date-parts":[[2017,10]]},"abstract":"<jats:p>\n                    The frequency of hepatitis C virus (HCV) infection remains high in patients with chronic kidney disease (CKD) and plays a detrimental role in mortality in this population. According to the latest survey, the adjusted hazard ratio for HCV-positive versus HCV-negative patients on long-term dialysis was 1.12 (95% CI, 1.05 to 1.20) and 1.10 (95% CI, 0.98 to 1.22) for all-cause and cardiovascular mortality, respectively. An impairment on quality of life has also been documented in HCV-infected patients undergoing regular dialysis. Most clinicians have been so far reluctant to treat hepatitis C in patients with advanced CKD, due to concerns regarding low efficacy and safety of interferon-based regimens. The advent of all-oral, direct-acting antivirals (DAAs) has revolutionized treatment paradigms for HCV, including patients with other comorbidities such as CKD. Two combinations of DAAs have been recently approved for the treatment of HCV in advanced CKD: elbasvir\/grazoprevir (evaluated in 1 randomized controlled trial) and ombitasvir\/paritaprevir\/ritonavir\/dasabuvir with or without ribavirin (examined in some observational, single-arm studies). These antiviral combinations have provided high safety and efficacy (SVR12 rates &gt;90%) in HCV-infected patients with stage 4\u20135 CKD. Sofosbuvir, a nucleotide analogue inhibitor of the HCV NS5B polymerase, is the cornerstone of most anti-HCV current regimens but is not currently recommended for patients with severe renal insufficiency (eGFR &lt;30 mL\/min per 1.73 m\n                    <jats:sup>2<\/jats:sup>\n                    ). However, several small-sized studies have been published on the safety and efficacy of sofosbuvir-based regimens for patients with hepatitis C on maintenance dialysis&gt;; overall, the viral response was satisfactory (SVR12 rates ranging between 58% and 100%) with a few drug-related drop-outs. Studies are in progress to assess whether ribavirin-free antiviral combinations with novel DAAs are a viable option for patients with severe renal impairment and chronic HCV infection.\n                  <\/jats:p>","DOI":"10.5301\/ijao.5000613","type":"journal-article","created":{"date-parts":[[2017,7,14]],"date-time":"2017-07-14T10:02:09Z","timestamp":1500026529000},"page":"531-541","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Direct-acting Antivirals for Hepatitis C Virus in Patients on Maintenance Dialysis"],"prefix":"10.1177","volume":"40","author":[{"given":"Fabrizio","family":"Fabrizi","sequence":"first","affiliation":[{"name":"Division of Nephrology, Maggiore Hospital and IRCCS Foundation, University of Milan, Milan - Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca M.","family":"Donato","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Maggiore Hospital and IRCCS Foundation, Milan - Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piergiorgio","family":"Messa","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Maggiore Hospital and IRCCS Foundation, University of Milan, Milan - Italy"},{"name":"Division of Nephrology, University School of Medicine and Maggiore Hospital, IRCCS Foundation, Milan - Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2017,8,7]]},"reference":[{"key":"bibr1-ijao.5000613","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.07940716"},{"issue":"8","key":"bibr2-ijao.5000613","doi-asserted-by":"crossref","first-page":"e0135476","DOI":"10.1371\/journal.pone.0135476","volume":"10","author":"Kwon E.","year":"2015","journal-title":"PLoS One."},{"key":"bibr3-ijao.5000613","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0000000000000391"},{"key":"bibr4-ijao.5000613","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2012.01633.x"},{"key":"bibr5-ijao.5000613","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12276"},{"key":"bibr6-ijao.5000613","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.09.001"},{"key":"bibr7-ijao.5000613","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12641"},{"issue":"11","key":"bibr8-ijao.5000613","first-page":"921","volume":"49","author":"Makhlough A.","year":"2008","journal-title":"Singapore Med J."},{"key":"bibr9-ijao.5000613","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-12-265"},{"key":"bibr10-ijao.5000613","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.23486"},{"key":"bibr11-ijao.5000613","doi-asserted-by":"publisher","DOI":"10.4103\/1319-2442.132236"},{"issue":"2","key":"bibr12-ijao.5000613","first-page":"133","volume":"7","author":"Zahran A.M.","year":"2014","journal-title":"Arab J Nephrol Transplant."},{"key":"bibr13-ijao.5000613","doi-asserted-by":"publisher","DOI":"10.4103\/1319-2442.144319"},{"key":"bibr14-ijao.5000613","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.24008"},{"key":"bibr15-ijao.5000613","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-015-0238-z"},{"key":"bibr16-ijao.5000613","doi-asserted-by":"publisher","DOI":"10.4103\/1319-2442.152555"},{"key":"bibr17-ijao.5000613","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/6841628"},{"key":"bibr18-ijao.5000613","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2012.10.009"},{"key":"bibr19-ijao.5000613","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2013.08.133"},{"key":"bibr20-ijao.5000613","doi-asserted-by":"publisher","DOI":"10.17554\/j.issn.2224-3992.2014.03.470"},{"key":"bibr21-ijao.5000613","doi-asserted-by":"publisher","DOI":"10.2147\/HMER.S72429"},{"key":"bibr22-ijao.5000613","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.04.045"},{"key":"bibr23-ijao.5000613","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315722"},{"key":"bibr24-ijao.5000613","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.08.015"},{"key":"bibr25-ijao.5000613","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60159-3"},{"key":"bibr26-ijao.5000613","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.02.078"},{"key":"bibr27-ijao.5000613","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12664"},{"key":"bibr28-ijao.5000613","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2017.01.037"},{"key":"bibr29-ijao.5000613","doi-asserted-by":"publisher","DOI":"10.1620\/tjem.241.45"},{"key":"bibr30-ijao.5000613","author":"Weizel T.","year":"2017","journal-title":"J Viral Hepat."},{"key":"bibr31-ijao.5000613","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00349-9"},{"key":"bibr32-ijao.5000613","unstructured":"Gilead. Sofosbuvir for treatment of chronic hepatitis C infection. Antiviral drugs advisory committed meeting briefing document. 2013 Oct 25. http:\/\/www.fda.gov\/downloads\/advisorycommittees\/committessmeetingmaterials\/drugs\/antiviraldrugsadviso-rycommittee\/ucm371877.pdf. Accessed June 6, 2017."},{"key":"bibr33-ijao.5000613","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.07.051"},{"key":"bibr34-ijao.5000613","unstructured":"FDA Drug Safety Communication. FDA warns of serious slowing of the heart rate when antiarrhythmic drug amiodarone is used with hepatitis C treatment containing sofosbuvir (Harvoni) or Sovaldi in combination with another Direct Acting Antiviral drug. https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm439484.htm. Accessed June 6, 2017."},{"key":"bibr35-ijao.5000613","unstructured":"GaneE., RobsonR., BonaciniM., MaliakkalB., KirbyB., LiuL. Safety, antiviral efficacy and pharmacokinetics of sofosbuvir in patients with severe renal impairment. 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Boston, MA, USA, 2014. Hepatology 2014; 60 (Abstract 966). http:\/\/www.natap.org\/2014\/AASLD\/AASLD_85.htm. Accessed June 6, 2017."},{"key":"bibr36-ijao.5000613","doi-asserted-by":"publisher","DOI":"10.3109\/23744235.2015.1078908"},{"key":"bibr37-ijao.5000613","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.06.004"},{"key":"bibr38-ijao.5000613","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.02.044"},{"key":"bibr39-ijao.5000613","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13078"},{"key":"bibr40-ijao.5000613","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13025"},{"key":"bibr41-ijao.5000613","doi-asserted-by":"publisher","DOI":"10.1111\/tri.12799"},{"key":"bibr42-ijao.5000613","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0000000000000640"},{"key":"bibr43-ijao.5000613","doi-asserted-by":"publisher","DOI":"10.1007\/s12664-017-0735-7"},{"issue":"1","key":"bibr44-ijao.5000613","first-page":"23","volume":"5","author":"Aggarwal A.","year":"2017","journal-title":"J Clin Transl Hepatol."},{"key":"bibr45-ijao.5000613","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12348"},{"key":"bibr46-ijao.5000613","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-015-3756-z"},{"key":"bibr47-ijao.5000613","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13102"},{"key":"bibr48-ijao.5000613","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-016-1174-4"},{"key":"bibr49-ijao.5000613","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-016-1162-8"},{"key":"bibr50-ijao.5000613","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.12407"},{"key":"bibr51-ijao.5000613","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v4.i3.88"},{"key":"bibr52-ijao.5000613","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12553"},{"key":"bibr53-ijao.5000613","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/12.7.1394"},{"key":"bibr54-ijao.5000613","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1996.403"},{"key":"bibr55-ijao.5000613","doi-asserted-by":"publisher","DOI":"10.1177\/039139880903200801"},{"key":"bibr56-ijao.5000613","unstructured":"AASLD\/IDSA Recommendations for testing, managing, and treating hepatitis C virus. http:\/\/hcvguidelines.org. Accessed June 6, 2017."}],"container-title":["The International Journal of Artificial Organs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.5301\/ijao.5000613","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.5301\/ijao.5000613","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.5301\/ijao.5000613","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T19:40:52Z","timestamp":1777491652000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.5301\/ijao.5000613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,7]]},"references-count":56,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["10.5301\/ijao.5000613"],"URL":"https:\/\/doi.org\/10.5301\/ijao.5000613","relation":{},"ISSN":["0391-3988","1724-6040"],"issn-type":[{"value":"0391-3988","type":"print"},{"value":"1724-6040","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,7]]}}}